75N93024C00026
Definitive Contract
Overview
Government Description
Development Of an Ultrasensitive, Rapid and Easy-to Use at-home Molecular Test for Hcv, Hbv and HIV
Awardee
Awarding / Funding Agency
Place of Performance
Chicago, IL 60654 United States
Pricing
Fixed Price
Set Aside
Small Business Set Aside - Total (SBA)
Extent Competed
Full And Open Competition After Exclusion Of Sources
Related Opportunity
SBIRPHS20241
Cubit Diagnostics was awarded
Definitive Contract 75N93024C00026 (75N930-24-C-00026)
for Development Of An Ultrasensitive, Rapid And Easy-To Use At-Home Molecular Test For Hcv, Hbv And Hiv
worth up to $299,961
by the National Institute of Allergy and Infectious Diseases
in August 2024.
The contract
has a duration of 8 months and
was awarded
with a Small Business Total set aside
with
NAICS 541715 and
PSC AN12
via direct negotiation acquisition procedures with 9 bids received.
SBIR Details
Research Type
Small Business Innovation Research Program (SBIR) Phase I
Title
DEVELOPMENT OF AN ULTRASENSITIVE, RAPID AND EASY-TO USE AT-HOME MOLECULAR TEST FOR HCV, HBV AND HIV
Abstract
Multiplexed Patient Administered Diagnostics for Hepatitis B, Hepatitis C, and HIV: HIV and viral hepatitis infections share common modes of transmission and social and structural barriers to accessing care and services among key populations. Coinfection with HIV significantly impacts the pathogenesis of HBV and HCV and is associated with reduced spontaneous clearance of HCV and HBsAg, higher rates of chronicity and occult HBV, higher HCV viral loads, rapid disease progression, and increased risk of morbidity and mortality due to cirrhosis and HCC. Integrated strategies for screening and diagnosis of HIV and viral hepatitis infections are therefore critical to an effective global health response. This contract aims to develop a nucleic acid amplification test for detection of HIV and HBV from whole capillary blood using the Cubit platform.
Research Objective
The goal of phase I is to establish the technical merit, feasibility, and commercial potential of proposed R&D efforts and determine the quality of performance of the small business awardee organization.
Topic Code
127
Agency Tracking Number
75N93024C00026-0-9999-0
Solicitation Number
PHS-2024-1
Contact
Status
(Complete)
Last Modified 7/22/24
Period of Performance
8/1/24
Start Date
4/30/25
Current End Date
4/30/25
Potential End Date
Obligations
$300.0K
Total Obligated
$300.0K
Current Award
$300.0K
Potential Award
Award Hierarchy
Definitive Contract
75N93024C00026
Subcontracts
Activity Timeline
People
Suggested agency contacts for 75N93024C00026
Competition
Number of Bidders
9
Solicitation Procedures
Negotiated Proposal/Quote
Evaluated Preference
None
Commercial Item Acquisition
Commercial Item Procedures Not Used
Simplified Procedures for Commercial Items
No
Other Categorizations
Subcontracting Plan
Plan Not Required
Cost Accounting Standards
Exempt
Business Size Determination
Small Business
Awardee UEI
MX5XL9PAEUB9
Awardee CAGE
9JR13
Agency Detail
Awarding Office
75N930 NATIONAL INSTITUTES OF HEALTH NIAID
Funding Office
75N930
Created By
hhspfinn
Last Modified By
hhspfinn
Approved By
hhspfinn
Legislative
Legislative Mandates
None Applicable
Performance District
IL-07
Senators
Richard Durbin
Tammy Duckworth
Tammy Duckworth
Representative
Danny Davis
Modified: 7/22/24